US20200190477A1 - Efficient induction of definitive endoderm from pluripotent stem cells - Google Patents
Efficient induction of definitive endoderm from pluripotent stem cells Download PDFInfo
- Publication number
- US20200190477A1 US20200190477A1 US16/694,040 US201916694040A US2020190477A1 US 20200190477 A1 US20200190477 A1 US 20200190477A1 US 201916694040 A US201916694040 A US 201916694040A US 2020190477 A1 US2020190477 A1 US 2020190477A1
- Authority
- US
- United States
- Prior art keywords
- cells
- chir
- concentration
- stem cells
- activin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001900 endoderm Anatomy 0.000 title claims abstract description 24
- 210000001778 pluripotent stem cell Anatomy 0.000 title abstract description 13
- 230000006698 induction Effects 0.000 title description 34
- 210000004027 cell Anatomy 0.000 claims abstract description 198
- 238000000034 method Methods 0.000 claims abstract description 150
- 210000001811 primitive streak Anatomy 0.000 claims abstract description 24
- 241000766026 Coregonus nasus Species 0.000 claims description 201
- 108010023082 activin A Proteins 0.000 claims description 150
- 210000004039 endoderm cell Anatomy 0.000 claims description 54
- 210000000130 stem cell Anatomy 0.000 claims description 54
- 238000011534 incubation Methods 0.000 claims description 34
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 33
- 239000002609 medium Substances 0.000 claims description 30
- 230000004069 differentiation Effects 0.000 claims description 23
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 14
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000035800 maturation Effects 0.000 abstract description 2
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 38
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 34
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 230000037452 priming Effects 0.000 description 15
- 241000607479 Yersinia pestis Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 12
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 11
- 101150019946 Gsk3b gene Proteins 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 6
- 108050003627 Wnt Proteins 0.000 description 6
- 102000013814 Wnt Human genes 0.000 description 6
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 102000015735 Beta-catenin Human genes 0.000 description 5
- 108060000903 Beta-catenin Proteins 0.000 description 5
- 108700031316 Goosecoid Proteins 0.000 description 5
- 102000050057 Goosecoid Human genes 0.000 description 5
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 5
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 4
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 210000001109 blastomere Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000000630 fibrocyte Anatomy 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 230000009996 pancreatic endocrine effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 102400001244 Cerebellin Human genes 0.000 description 2
- 101800001299 Cerebellin Proteins 0.000 description 2
- 102100030751 Eomesodermin homolog Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102100024208 Homeobox protein MIXL1 Human genes 0.000 description 2
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 2
- 101001052462 Homo sapiens Homeobox protein MIXL1 Proteins 0.000 description 2
- -1 NANOG Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101100310647 Homo sapiens SOX17 gene Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 101100445364 Mus musculus Eomes gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101150007417 SOX17 gene Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000006757 Wnt Receptors Human genes 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 101100445365 Xenopus laevis eomes gene Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000019494 establishment of tissue polarity Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 101150070243 ptf1a gene Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Definitions
- the present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.
- DE cells from pluripotent embryonic stem (ES) cells has been reported for both mouse and human in, e.g., WO2005/116073, WO2005/063971, and US 2006/0148081.
- the generation of pancreatic endoderm (PE) cells from DE cells is necessary for the generation of insulin-producing beta cells for the treatment of diabetes.
- CHIR is a glycogen synthase kinase 3 beta (Gsk3b) inhibitor and a known component of a defined tissue culture medium to maintain mouse embryonic stem cells in the pluripotent state (Ying et al Nature 453, 519-523).
- Gsk3b has multiple targets but is mainly known to regulate degradation and/or nuclear transfer of beta-catenin.
- the role of stabilized betacatenin in PS formation from human embryonic stem cells (hESC) has been described using other glycogen synthase kinase 3 beta (Gsk3b) inhibitors such as BIO and Wnt3a.
- CHIR is the most selective Gsk3b-inhibitor reported to date.
- the present invention relates to the utilization of CHIR without AA, at a defined concentration range to treat pluripotent stem cells prior to AA-mediated definitive endoderm induction compared to the conventional induction protocol for obtaining DE (D'Amour protocol, as described in Kroon et al. 2008).
- This sequential exposure, first to CHIR and then to AA, is essential and reflects successive PS formation (induced by CHIR) followed by more efficient and rapid DE formation by AA.
- the present invention relates to the discrete and successive control of induction of first PS then followed by DE leading to an overall more efficient, with earlier peak of SOX17 expression and robust DE protocol.
- D0 Undifferentiated cells before any treatment
- Ctrl No Chir treatment
- D1 Cells are left in RPMI during priming period, followed by AA D2 and AA+serum replacement (B27) from D3 onwards.
- D'Am No Chir treatment, protocol according to Kroon et al., Nat. Biotech., 2008 (1 day ActivinA 100 ng/ml+Wnt 25 ng/ml, 2 days ActivinA100 ng/ml+0.2% FBS)
- D1 1 day after Chir addition
- D2-4 1-3d after AA addition All gene expression graphs show Log 10 values.
- FIG. 1 shows the CHIR DEprotocol nomenclature and overview. The protocol has been confirmed in 7 different pluripotent stem cell lines: SA121, SA181, SA461, SA167 (human ESCs) and chIPS2, chIPS3, chIPS4 (human iPSCs).
- FIG. 2 shows transcriptional expression of PS markers Brachyury (T), MIXL1, EOMES and Goosecoid (GSC) after 24 h of CHIR treatment (D1) in hES SA121 ( FIG. 2A ) and chIPS4 ( FIG. 2B ), compared to non-treated cells. T protein levels were also confirmed with ICC ( FIG. 2C ). T fold inductions after 24 h CHIR treatment have spanned between 500-100000 compared to undifferentiated cells (n>60). Bars show Log 10 values relative to undifferentiated cells D0.
- FIG. 3 shows gene expression of DE markers (SOX17, CXCR4, FOXA2, CER) one day after replacing CHIR with Activin A (AA) compared to with cells that were not pretreated with CHIR. Expression is shown both in hESC SA121 ( FIG. 3A ) and iPSC chIPS4 ( FIG. 3B ). Bars show Log 10 values relative to undifferentiated cells D0.
- FIG. 4 shows hESC SA121 ( 4 A-B) and iPSC chIPS4 ( 4 C) cells treated with either CHIR (3 ⁇ M), BIO (0.5 uM), Wnt3a (200 ng/ml) or AA alone (100 ng/ml) for 24 h (D1) prior to 2d AA treatment (D3). Additionally, D'Amour (protocol as described in Kroon et al 2008) was analyzed. Expression of Brachyury and SOX17 was analyzed. hES cells treated with AA or BIO for the first 24 h did not survive until day 3.
- FIG. 5 shows gene expression levels of DE markers SOX17, FOXA2 and CXCR4 ( FIG. 5AC ) and OCT4 ( FIG. 5E ) after CHIR induction compared to D'Amour and quantified ICC protein levels of SOX17/OCT4 in chIPS4 cells ( FIG. 5D , F). Corresponding % of cells positively stained for OCT4 and SOX17 (D1-3) are also indicated in Table 2.
- chIPS/SA121 DE cells using either of the two protocols, were further differentiated towards pancreatic endoderm (PE) using a previously published PE differentiation protocol (Ameri et al 2010). Cells were analyzed after seven days of PE induction using ICC for PDX1 protein levels.
- PE pancreatic endoderm
- FIG. 6 shows gene expression of SOX17 D3 in hES SA121 ( FIG. 6A ) or chIPS4 ( FIG. 6C ) treated with either only RPMI, AA and Wnt3a or CHIR D1 followed by treatment with either AA or a combination of AA and Wnt3a D2 and AA D3 ( FIG. 6A ).
- Cells were also treated with either CHIR D1 and AA D2 (“CHIR”), D'Amour, or CHIR on top of D'Amour and were analyzed for SOX17 expression ( FIG. 6B ) and morphology ( FIG. 6D ).
- CHIR D1 and AA D2 (“CHIR”)
- D'Amour D'Amour
- CHIR CHIR on top of D'Amour
- FIG. 7 shows that CHIR was titrated at concentrations between 1-7 uM and analysed after 24 h (D1) and after 2d of following AA treatment (D3). CHIR 0.5-1 uM and CHIR 7 uM did not survive D3. Brachyury expression was analysed after 24 h treatment in SA121 ( FIG. 7A ) and chIPS cells ( FIG. 7C ). SOX17 expression was analysed D3 in SA121 ( FIG. 7B ) and chIPS cells ( FIG. 7D )).
- FIG. 8 shows gene expression of SOX17 D3 after CHIR pre-treatment or after the D'Amour protocol in the mTeSR system ( FIG. 8 ).
- FIG. 9 shows gene expression levels of markers Brachyury and SOX17 at D0, D2 and D3 when cultured on MEF feeders.
- the present invention also relates to a method for differentiation of stem cells into definitive endoderm comprising the steps of:
- the present invention relates to a faster and more pronounced peak of SOX17 expression and a more robust method of differentiating human pluripotent stem cells to obtain definitive endoderm.
- the present invention relates to a method for differentiation of stem cells into definitive endoderm comprising the steps of incubating pluripotent stem cells in a medium comprising at least 2 ⁇ M CHIR and subsequently incubating these cells in a medium comprising Activin A (AA).
- the present inventors have found that using CHIR alone for 24 h prior to further addition of AA, induced a significant and dose dependent upregulation of PS markers such as Brachyury, Mixl1, Eomes and Goosecoid (GSC) during these 24 h.
- PS markers such as Brachyury, Mixl1, Eomes and Goosecoid (GSC) during these 24 h.
- the present inventors have surprisingly found that in the subsequent incubation with AA to induce DE, DE induction as measured by SOX17 expression, peaked at an earlier time point and with higher fold change when compared to cultures without CHIR pre-incubation or when compared to the conventional D'Amour protocol (Novocell, Nature Biotec 2006, 2008).
- the present inventors surprisingly found that the method of the present invention was more efficient and showed a faster induction of Sox17 mRNA expression than other known protocols for DE Induction.
- the CHIR-mediated effect has been reproduced both in other culture systems (mTeSR media and conventional ES media on mouse embryonic feeder (MEF) cells) and across different cell lines (SA121, SA181, SA461, SA167, chIPS2, chIPS3, chIPS4), showing that the effect is not dependent on the cell line or the DEF media culture system.
- Human embryonic stem cells may be derived from single blastomeres without the destruction of the embryo (Klimanskaya et al. 2006; Chung et al. 2008; Geens et al. 2009).
- Cell lines chIPS2, chIPS3, chIPS4 are iPS cell lines.
- CHIR CHIR promotes high cell densities after AA is added. Dose dependency of CHIR in PS induction will allow future optimization of possible pre-patterning influences when initiating AA treatment. The subsequent order of added factors decreases the amount of signaling pathways that are activated in parallel. Minimizing the amount of factors that may influence the efficiency should promote robustness and reproducibility.
- the present inventors have surprisingly found that the CHIR-priming step is unique for DE induction and was superior when compared to BIO or Wnt3a when it comes to efficiency peak of SOX17 expression and robustness.
- hESCs Human embryonic stem cells
- iPSCs human induced pluripotent stem cells
- the present inventors have surprisingly found the CHIR-priming step resulted in a remarkably fast induction of SOX17 by AA peaking already after 1 day which is in contrast to AA alone where the peak is seen only after 3-4 days.
- the sequential incubation with CHIR followed by AA is essential for DE formation to favourable levels.
- the pancreatic endocrine cells obtainable by the method according to the invention are insulin producing cells, optionally together with cells differentiated towards glucagon, somatostatin, pancreatic polypeptide, and/or ghrelin producing cells.
- insulin producing cells refers to cells that produce and store or secrete detectable amounts of insulin.
- Insulin producing cells can be individual cells or collections of cells.
- the cell population comprising pancreatic cells is obtained from a somatic cell population.
- the somatic cell population has been induced to de-differentiate in to an embryonic-like stem (ES, e.g., a pluripotent) cell.
- ES embryonic-like stem
- IPS induced pluripotent stem cells
- the cell population comprising pancreatic cells is obtained from embryonic stem (ES, e.g., pluripotent) cells.
- ES embryonic stem
- the cell population comprising pancreatic cells is pluripotent cells such as ES like-cells.
- the cell population comprising pancreatic cells is embryonic differentiated stem (ES or pluripotent) cells. Differentiation takes place in embryoid bodies and/or in monolayer cell cultures or a combination thereof.
- ES embryonic differentiated stem
- the cell population is a population of stem cells.
- the cell population is a population of stem cells differentiated to the pancreatic endocrine lineage.
- Stem cells are undifferentiated cells defined by their ability at the single cell level to both self-renew and differentiate to produce progeny cells, including self-renewing progenitors, non-renewing progenitors, and terminally differentiated cells. Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation and to contribute substantially to most, if not all, tissues following injection into blastocysts.
- Stem cells are classified by their developmental potential as: (1) totipotent, meaning able to give rise to all embryonic and extraembryonic cell types; (2) pluripotent, meaning able to give rise to all embryonic cell types; (3) multi-potent, meaning able to give rise to a subset of cell lineages, but all within a particular tissue, organ, or physiological system (for example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self-renewal), blood cell restricted oligopotent progenitors and all cell types and elements (e.g., platelets) that are normal components of the blood); (4) oligopotent, meaning able to give rise to a more restricted subset of cell lineages than multi-potent stem cells; and (5) unipotent, meaning able to give rise to a single cell lineage (e.g., spermatogenic stem cells).
- HSC hematopoietic stem cells
- a protocol for obtaining pancreatic cells from stem cells is exemplified by, but not limited to, the protocols described in D'Amour, K. A. et al. (2006), Nat Biotechnol 24, 1392-401; Jiang, J. et al. (2007), Stem Cells 25, 1940-53; and Kroon, E. et al. (2008), Nat Biotechnol 26, 443-452.
- a protocol for obtaining pancreatic cells from somatic cells or somatic cells induced to de-differentiate into pluripotent cells such as ES like-cells is exemplified by, but not limited to, the protocols described in Aoi, T. et al. (2008), Science 321 (no. 5889), 699-702; D'Amour, K. A. et al. (2006), Nat Biotechnol 24, 1392-401; Jiang, J. et al. (2007), Stem Cells 25, 1940-53; Kroon, E. et al. (2008), Nat Biotechnol 26, 443-452; Takahashi, K. et al. (2007), Cell 131, 861-72; Takahashi, K., and Yamanaka, S. (2006), Cell 126, 663-76; and Wernig, M. et al. (2007), Nature 448, 318-24.
- differentiate refers to a process where cells progress from an undifferentiated state to a differentiated state, from an immature state to a less immature state or from an immature state to a mature state.
- characteristics markers like Pdx1, Nkx6.1, and Ptf1a.
- Mature or differentiated pancreatic cells do not proliferate and do secrete high levels of pancreatic endocrine hormones or digestive enzymes.
- fully differentiated beta cells secrete insulin at high levels in response to glucose. Changes in cell interaction and maturation occur as cells lose markers of undifferentiated cells or gain markers of differentiated cells.
- differentiation factor refers to a compound added to pancreatic cells to enhance their differentiation to mature endocrine cells also containing insulin producing beta cells.
- exemplary differentiation factors include hepatocyte growth factor, keratinocyte growth factor, exendin-4, basic fibroblast growth factor, insulin-like growth factor-1, nerve growth factor, epidermal growth factor platelet-derived growth factor, and glucagon-like peptide 1.
- differentiation of the cells comprises culturing the cells in a medium comprising one or more differentiation factors.
- human pluripotent stem cells refers to cells that may be derived from any source and that are capable, under appropriate conditions, of producing human progeny of different cell types that are derivatives of all of the 3 germinal layers (endoderm, mesoderm, and ectoderm). hPS cells may have the ability to form a teratoma in 8-12 week old SCID mice and/or the ability to form identifiable cells of all three germ layers in tissue culture. Included in the definition of human pluripotent stem cells are embryonic cells of various types including human blastocyst derived stem (hBS) cells in 30 literature often denoted as human embryonic stem (hES) cells, (see, e.g., Thomson et al.
- hBS human blastocyst derived stem
- hES human embryonic stem
- hPS cells suitable for use may be obtained from developing embryos.
- suitable hPS cells may be obtained from established cell lines and/or human induced pluripotent stem (hiPS) cells.
- hiPS cells refers to human induced pluripotent stem cells.
- the term “blastocyst-derived stem cell” is denoted BS cell, and the human form is termed “hBS cells”.
- BS cell the human form
- hBS cells human embryonic stem cells
- the pluripotent stem cells used in the present invention can thus be embryonic stem cells prepared from blastocysts, as described in e.g. WO 03/055992 and WO 2007/042225, or be commercially available hBS cells or cell lines.
- any human pluripotent stem cell can be used in the present invention, including differentiated adult cells which are reprogrammed to pluripotent cells by e.g. the treating adult cells with certain transcription factors, such as OCT4, SOX2, NANOG, and LIN28 as disclosed in Yu, et al., 2007, Takahashi et al. 2007 and Yu et al 2009.
- feeder cells are intended to mean supporting cell types used alone or in combination.
- the cell type may further be of human or other species origin.
- the tissue from which the feeder cells may be derived include embryonic, fetal, neonatal, juvenile or adult tissue, and it further includes tissue derived from skin, including foreskin, umbilical chord, muscle, lung, epithelium, placenta, fallopian tube, glandula, stroma or breast.
- the feeder cells may be derived from cell types pertaining to the group consisting of human fibroblasts, fibrocytes, myocytes, keratinocytes, endothelial cells and epithelial cells.
- Examples of specific cell types that may be used for deriving feeder cells include embryonic fibroblasts, extraembryonic endodermal cells, extraembryonic mesoderm cells, fetal fibroblasts and/or fibrocytes, fetal muscle cells, fetal skin cells, fetal lung cells, fetal endothelial cells, fetal epithelial cells, umbilical chord mesenchymal cells, placental fibroblasts and/or fibrocytes, placental endothelial cells,
- MEF cells is intended to mean mouse embryonic fibroblasts.
- CHIR glycogen synthase kinase 3 beta
- CHIR is at least 12 hours, such as 24 hours.
- D'Am D'Amour protocol (Kroon et al., 2008)
- DE definitive endoderm
- FGF basic fibroblast growth factor (FGF2)
- Gsk3b glycogen synthase kinase 3 beta hBSC; human blastocyst-derived stem cells
- hESC human embryonic stem cells
- hIPSC human induced pluripotent cells
- hPSC human pluripotent stem cells
- KO-SR knockout serum replacement RNA: ribonucleic acid PCR: polymerase chain reaction
- PS primitive streak
- SOX17 SRY (sex determining region Y)-box 17
- the DE protocol was confirmed in two different feeder free (DEF, mTeSR) culture systems and one feeder dependent (MEF-ES) culture system.
- hES cells SA121 and chIPS4 were grown on human fibronectin (Sigma) in DEF culture media (Cellartis) with 30 ng/ml bFGF (Invitrogen) and 10 ng/ml Noggin (Peprotech) in 6-96 well plates.
- Cells were single cell passaged with Rock inhibitor Y-27632 (Calbiochem) and seeded at a density of 40000 cells/cm2 for experiments. Experiments were initiated 4d after passage.
- hES cells were cluster passaged from feeders (MEFs) to Matrigel (BD Biosciences) in mTeSR1 media (Cell Signaling Techologies) and passaged further with Dispase (BD Biosciences) according to the culture system protocol. DE was initiated once clusters started to touch eachother
- hES cells (SA121) were passaged on gelatine-coated plates pre-seeded with MEFs in hES media (KO-DMEM, PEST, Glutamax, NEAA, 2-mercaptoethanol, KO serum replacement, 10 ng/ml bFGF). DE was initiated at 80% confluency.
- Confluent cultures were washed once in RPM11640 (Invitrogen) before 24 hour pretreatment with 0.5-7 ⁇ M CHIR99021 (Stemgent) in RPMI.
- Control cells were left untreated in RPMI and D'Amour cells were either left in RPMI or treated with AA (Peprotech)+Wnt3a (R&D Systems) without pre-treatment depending on experimental setup.
- FIG. 1 Overview of the CHIR Definitive Endoderm protocol can be found in FIG. 1 .
- the protocol has been confirmed in 7 different cell lines: SA121, SA181, SA461, SA167 (hESC) and chIPS2, chIPS3, chIPS4 (hiPSC).
- Day 1 medium was premixed (CHIR 3 ⁇ M in prewarmed RPMI + PEST) and gently added to cell culture. Volumes were adjusted according to plate formats.
- Day 2 Cells were washed carefully in prewarmed (37° C.) RPMI before media change. Day 2 medium was premixed (100 ng/ml Activin A in prewarmed RPMI + 0.1% PEST) and gently added to cell culture.
- Day 3 Day 3&4 mediums were premixed (100 ng/ml Activin A and 2% B27 in prewarmed RPMI + 0.1% PEST) and gently added to cell culture.
- Day 4 DE was harvested or reseeded for further differentiation. Cells were checked under the microscope every day.
- RNA samples were collected after 24 h pre-treatment (D1), after 1 day of AA treatment (D2) and after 1-2d of AA+B27 treatment (D3-4). Total RNA was extracted with the Rneasy Plus Mini kit (Qiagen) and quantitative real-time PCR was performed using the StepOnePLus system (Applied Biosystems).
- Undifferentiated SA121 hES and chIPS4 iPS cells in DEF media were cultured either in RPMI without CHIR (Ctrl D1) or treated for 24 h with CHIR in RPMI (CHIR D1). The cells were then washed to ensure absence of CHIR and then both conditions were treated with 1d AA (Ctrl and CHIR d2). After 1d CHIR treatment, PS markers such as Brachyury (T), MIXL1, EOMES and GSC were highly upregulated compared to non pre-treated cells ( FIG. 2A-C ). T fold inductions after 24 h CHIR treatment spanned between 500-100000 compared to undifferentiated cells (d0). T protein levels were also confirmed with ICC ( FIG. 2C ).
- SOX17 expression peaked already after one day of AA treatment when cells were subjected to CHIR for 24 h before AA induction.
- Cells in AA-containing media that were not pre-treated with CHIR (ctrl) did not show same speed or efficiency in Sox17 induction.
- CHIR has a direct capacity to induce PS markers after 24 h treatment (D1) and resulted in a remarkably higher ability for AA to induce DE when added (D2). Brachyury was greatly repressed once AA was added indicating that the cells were differentiating in a highly stepwise order.
- hES SA121 and ChIPS4 cells were treated with either CHIR (3 ⁇ M), BIO (0.5 uM), Wnt3a (200 ng/ml) or AA alone (100 ng/ml) for 24 h prior to AA addition to show CHIR specificity (d1). Additionally, D'Amour (protocol as described in Kroon et al 2008) was tested in parallel.
- Undifferentiated ChIPS4 cells (d0) were either pre-treated for 24 h with CHIR (3 uM) or directly exposed to AA (100 ng/ml) and Wnta3a (25 ng/ml) according to Kroon et al 2008. The cells were then washed and AA was added for 1-4d. See Table 1 for detailed setup.
- CHIR treatment was superior in upregulating both T (mRNA D1) and SOX17 after CHIR pre-treatment (mRNA, ICC D3) compared to D'Amour ( FIG. 5 and Table 2).
- mRNA D1 mRNA D1
- SOX17 SOX17 after CHIR pre-treatment
- ICC D3 D'Amour
- the most striking difference between the protocols could be seen in terms of morphology with a much higher degree of cell death during D'Amour treatment.
- chIPS4 cells treated with either the CHIR- or D'Amour-protocol were fixed and stained using a SOX17-specific ab and the images were quantified in respect of total amounts and the percentage of SOX17-positive cells. As shown in FIG.
- chIPS4 cells differentiated to DE were further differentiated towards pancreatic endoderm (PE) by using a previously published PE differentiation protocol (Ameri et al 2010). Seven days after the induction of PE differentiation the cells were fixed and analyzed by ICC using a PDX1 specific antibody. The results showed very modest PDX1-staining in the D'Amour-treated cells whereas the staining was evident in the CHIR pre-treated cells (data not shown). In parallel, mRNA was collected from the cells and the PDX1 expression was analyzed by real-time PCR.
- Cells were pre-treated 1d with either RPMI (ctrl), CHIR 3 uM, CHIR 3 uM+AA 100 ng/ml or 100 ng/ml AA+25 ng/ml Wnt3a (D'Amour) prior to addition of AA+/ ⁇ Wnt3a (25 ng/ml) d2 and AA d3 (Table 3).
- B27 was added in Ctrl and CHIR d3 and FBS to D'Amour d2-3.
- CHIR pretreatment replaces the requirement of both Wnt3a and AA during the first day of differentiation toward DE and also has a stabilizing effect leading to a more robust protocol.
- CHIR and exogenous AA may have counteracting effects that reduce overall efficiency and/or target different cell populations differently, resulting in higher levels of heterogeneity within the cell culture and increased inter-experimental variability. This suggests that PS induction/transition before adding AA to the media is an important and novel step to enhance protocol efficiency and robustness.
- Chir was titrated at concentrations between 1-7 uM and analyzed after 24 h Chir treatment (D1) and after 2d of following AA treatment (D3). CHIR 0.5-1 uM and CHIR 7 uM did not survive d3.
- the data indicates that PS formation is delayed at Chir concentrations under 1 uM, unabling further progression toward DE when AA is added.
Abstract
The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.
Description
- This application is a continuation of U.S. application Ser. No. 15/705,705, filed Sep. 15, 2017 (allowed) which is a continuation of U.S. application Ser. No. 14/127,296, filed Apr. 7, 2014 (Abandoned), which is a 35 U.S.C. § 371 National Stage application of International Application PCT/EP2012/062013, filed Jun. 21, 2012, which claims priority to European Patent Application 11170713.9, filed Jun. 21, 2011; the parent application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application 61/501,351; filed Jun. 27, 2011. The contents of all applications are incorporated herein by reference.
- The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.
- Transplantation of islets of Langerhans holds great promise to improve treatment of
Type 1 diabetes mellitus, but the scarcity of available donor islets is one obstacle that need to be addressed. Pluripotent stem cells can in principle generate unlimited numbers of beta cells for transplantation but reliable protocols for generating fully functional beta cells are not yet developed. The foregut derivatives; pancreas, lung, thyroid, liver, esophagus, and stomach originate from definitive endoderm (DE), one of the three germ layers that forms during gas-trulation. Induction of DE is the first critical step towards formation of differentiated cell types from endodermally derived tissues such as insulin producing beta cells of the pancreas. Formation of DE cells from pluripotent embryonic stem (ES) cells has been reported for both mouse and human in, e.g., WO2005/116073, WO2005/063971, and US 2006/0148081. The generation of pancreatic endoderm (PE) cells from DE cells is necessary for the generation of insulin-producing beta cells for the treatment of diabetes. - It is known that DE formation in the embryo passes through the intermediate step of primitive streak (PS) formation (a mesendodermal intermediate) which has the potential to form either mesoderm or DE. At the cellular level, all developmental processes are ultimately controlled by the cooperative actions of different signal transduction pathways. Among them, Wnt signaling is indispensable for orchestrating the complex cell behaviors that occur throughout development. Wnt signaling controls cell proliferation, stem cell maintenance and cell fate decisions, as well as organized cell movements and the establishment of tissue polarity. It is also frequently deregulated in human cancers and has been implicated in degenerative diseases. As a potential target for therapeutic intervention, it thus holds new promises in the fields of stem cell biology and regenerative medicine.
- Induction of DE has been described by the use of Activin A/Nodal with or without the combination of Wnt. In particular, the Wnt receptor ligand Wnt3a has previously been reported to contribute to efficient DE formation when incubated along with activin A (AA) during day 1 (24 h) of a 5 day AA-mediated induction of DE, ie., using the conventional D'Amour protocol (Kroon et al 2008, Nat Biotech, 2006).
- Attempts to group individual Wnt proteins into classes to which specific activities could be assigned have resulted in the subdivision of Wnts into ‘canonical’ or ‘non-canonical’, based on the ability of the former, but not the later, to induce beta-catenin/TCF signaling.
- CHIR is a
glycogen synthase kinase 3 beta (Gsk3b) inhibitor and a known component of a defined tissue culture medium to maintain mouse embryonic stem cells in the pluripotent state (Ying et al Nature 453, 519-523). Gsk3b has multiple targets but is mainly known to regulate degradation and/or nuclear transfer of beta-catenin. The role of stabilized betacatenin in PS formation from human embryonic stem cells (hESC) has been described using otherglycogen synthase kinase 3 beta (Gsk3b) inhibitors such as BIO and Wnt3a. However CHIR is the most selective Gsk3b-inhibitor reported to date. - Co-incubation of AA and CHIR reduces DE formation stability, leading to a less efficient and less robust protocol. The present invention relates to the utilization of CHIR without AA, at a defined concentration range to treat pluripotent stem cells prior to AA-mediated definitive endoderm induction compared to the conventional induction protocol for obtaining DE (D'Amour protocol, as described in Kroon et al. 2008). This sequential exposure, first to CHIR and then to AA, is essential and reflects successive PS formation (induced by CHIR) followed by more efficient and rapid DE formation by AA. The present invention relates to the discrete and successive control of induction of first PS then followed by DE leading to an overall more efficient, with earlier peak of SOX17 expression and robust DE protocol. These effects of CHIR cannot be reproduced with Wnt3a treatment.
- D0: Undifferentiated cells before any treatment
Ctrl: No Chir treatment D1. Cells are left in RPMI during priming period, followed by AA D2 and AA+serum replacement (B27) from D3 onwards.
D'Am: No Chir treatment, protocol according to Kroon et al., Nat. Biotech., 2008 (1 day ActivinA 100 ng/ml+Wnt 25 ng/ml, 2 days ActivinA100 ng/ml+0.2% FBS)
D1: 1 day after Chir addition
D2-4: 1-3d after AA addition
All gene expression graphs show Log 10 values. -
FIG. 1 shows the CHIR DEprotocol nomenclature and overview. The protocol has been confirmed in 7 different pluripotent stem cell lines: SA121, SA181, SA461, SA167 (human ESCs) and chIPS2, chIPS3, chIPS4 (human iPSCs). -
FIG. 2 shows transcriptional expression of PS markers Brachyury (T), MIXL1, EOMES and Goosecoid (GSC) after 24 h of CHIR treatment (D1) in hES SA121 (FIG. 2A ) and chIPS4 (FIG. 2B ), compared to non-treated cells. T protein levels were also confirmed with ICC (FIG. 2C ). T fold inductions after 24 h CHIR treatment have spanned between 500-100000 compared to undifferentiated cells (n>60). Bars showLog 10 values relative to undifferentiated cells D0. -
FIG. 3 shows gene expression of DE markers (SOX17, CXCR4, FOXA2, CER) one day after replacing CHIR with Activin A (AA) compared to with cells that were not pretreated with CHIR. Expression is shown both in hESC SA121 (FIG. 3A ) and iPSC chIPS4 (FIG. 3B ). Bars showLog 10 values relative to undifferentiated cells D0. -
FIG. 4 shows hESC SA121 (4A-B) and iPSC chIPS4 (4C) cells treated with either CHIR (3 μM), BIO (0.5 uM), Wnt3a (200 ng/ml) or AA alone (100 ng/ml) for 24 h (D1) prior to 2d AA treatment (D3). Additionally, D'Amour (protocol as described in Kroon et al 2008) was analyzed. Expression of Brachyury and SOX17 was analyzed. hES cells treated with AA or BIO for the first 24 h did not survive untilday 3. -
FIG. 5 shows gene expression levels of DE markers SOX17, FOXA2 and CXCR4 (FIG. 5AC ) and OCT4 (FIG. 5E ) after CHIR induction compared to D'Amour and quantified ICC protein levels of SOX17/OCT4 in chIPS4 cells (FIG. 5D , F). Corresponding % of cells positively stained for OCT4 and SOX17 (D1-3) are also indicated in Table 2. chIPS/SA121 DE cells, using either of the two protocols, were further differentiated towards pancreatic endoderm (PE) using a previously published PE differentiation protocol (Ameri et al 2010). Cells were analyzed after seven days of PE induction using ICC for PDX1 protein levels. In parallel, mRNA was collected from the cells and the PDX1 expression was analyzed by real-time PCR for both chIPS4 cells (FIG. 5G ) and SA121 cells (FIG. 5H ). The experiment was repeated twice in both cell lines (FIG. 5G , H). -
FIG. 6 shows gene expression of SOX17 D3 in hES SA121 (FIG. 6A ) or chIPS4 (FIG. 6C ) treated with either only RPMI, AA and Wnt3a or CHIR D1 followed by treatment with either AA or a combination of AA and Wnt3a D2 and AA D3 (FIG. 6A ). Cells were also treated with either CHIR D1 and AA D2 (“CHIR”), D'Amour, or CHIR on top of D'Amour and were analyzed for SOX17 expression (FIG. 6B ) and morphology (FIG. 6D ). -
FIG. 7 shows that CHIR was titrated at concentrations between 1-7 uM and analysed after 24 h (D1) and after 2d of following AA treatment (D3). CHIR 0.5-1 uM and CHIR 7 uM did not survive D3. Brachyury expression was analysed after 24 h treatment in SA121 (FIG. 7A ) and chIPS cells (FIG. 7C ). SOX17 expression was analysed D3 in SA121 (FIG. 7B ) and chIPS cells (FIG. 7D )). -
FIG. 8 shows gene expression of SOX17 D3 after CHIR pre-treatment or after the D'Amour protocol in the mTeSR system (FIG. 8 ). -
FIG. 9 shows gene expression levels of markers Brachyury and SOX17 at D0, D2 and D3 when cultured on MEF feeders. - The present invention also relates to a method for differentiation of stem cells into definitive endoderm comprising the steps of:
-
- a. first priming step of incubating stem cells in a medium comprising at least 2 μM CHIR, wherein activin A is not present during said priming step; and
- b. second subsequent step of incubating stem cells in a medium comprising activin A.
- The present invention relates to a faster and more pronounced peak of SOX17 expression and a more robust method of differentiating human pluripotent stem cells to obtain definitive endoderm.
- The present invention relates to a method for differentiation of stem cells into definitive endoderm comprising the steps of incubating pluripotent stem cells in a medium comprising at least 2 μM CHIR and subsequently incubating these cells in a medium comprising Activin A (AA).
- The present inventors have found that using CHIR alone for 24 h prior to further addition of AA, induced a significant and dose dependent upregulation of PS markers such as Brachyury, Mixl1, Eomes and Goosecoid (GSC) during these 24 h.
- The present inventors have surprisingly found that in the subsequent incubation with AA to induce DE, DE induction as measured by SOX17 expression, peaked at an earlier time point and with higher fold change when compared to cultures without CHIR pre-incubation or when compared to the conventional D'Amour protocol (Novocell, Nature Biotec 2006, 2008). The present inventors surprisingly found that the method of the present invention was more efficient and showed a faster induction of Sox17 mRNA expression than other known protocols for DE Induction.
- The CHIR-mediated effect has been reproduced both in other culture systems (mTeSR media and conventional ES media on mouse embryonic feeder (MEF) cells) and across different cell lines (SA121, SA181, SA461, SA167, chIPS2, chIPS3, chIPS4), showing that the effect is not dependent on the cell line or the DEF media culture system. Human embryonic stem cells may be derived from single blastomeres without the destruction of the embryo (Klimanskaya et al. 2006; Chung et al. 2008; Geens et al. 2009). Cell lines chIPS2, chIPS3, chIPS4 are iPS cell lines.
- The present inventors found that CHIR promotes high cell densities after AA is added. Dose dependency of CHIR in PS induction will allow future optimization of possible pre-patterning influences when initiating AA treatment. The subsequent order of added factors decreases the amount of signaling pathways that are activated in parallel. Minimizing the amount of factors that may influence the efficiency should promote robustness and reproducibility.
- The present inventors have surprisingly found that the CHIR-priming step is unique for DE induction and was superior when compared to BIO or Wnt3a when it comes to efficiency peak of SOX17 expression and robustness.
- Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs) from expandable pluripotent cultures were subjected to 24 h treatment of CHIR (2-7 μM) in plain RPMI-1640 medium. Following medium change to an AA containing RPMI-1640 medium, the DE induction commenced where SOX17 mRNA expression peaked after 2 days and SOX17 protein expression peaked after 3-4 days. Concentrations below 2 μM of CHIR caused a delayed induction of Brachyury to significantly lower levels and following subsequent AA stimulation the DE was not induced after 72 hrs. PS formation was delayed at CHIR concentrations under 1.5 μM thus disabling further progression toward DE when AA was added. The present inventors have surprisingly found that a concentration range greater or equal to 2 μM of CHIR for 24 hrs is important for the subsequent DE induction by AA.
- The present inventors have surprisingly found the CHIR-priming step resulted in a remarkably fast induction of SOX17 by AA peaking already after 1 day which is in contrast to AA alone where the peak is seen only after 3-4 days. The sequential incubation with CHIR followed by AA is essential for DE formation to favourable levels.
-
- 1. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
- c. first priming step of incubating stem cells in a medium comprising at least 2 μM CHIR, wherein activin A is not present during said priming step; and
- d. second subsequent step of incubating stem cells in a medium comprising activin A.
- 2. The method according to
embodiment 1, wherein said medium is RPMI-1640. - 3. The method according to any one of the preceding embodiments, wherein said stem cells are embryonic stem cells or induced pluripotent stem cells.
- 4. The method according to any one of the preceding embodiments, wherein said stem cells are embryonic stem cells.
- 5. The method according to
embodiment 3, wherein said stem cells are human embryonic stem cells. - 6. The method according to
embodiment 3, wherein said stem cells are induced pluripotent stem cells. - 7. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is at least about 2.5 μM, or at least 3 μM, such as in a range of about 2-20 uM, such as in a range of about 3.1-15 μM, or such as in a range of about 3.5-7 μM or such as in a range of about 3.5-6 μM, or such as in a range of about 3.5-5 μM.
- 8. The method according to embodiment 7, wherein the concentration of CHIR is at least about 2 μM.
- 9. The method according to embodiment 7, wherein the concentration of CHIR is at least about 2.5 μM.
- 10. The method according to embodiment 7, wherein the concentration of CHIR is at least about 3 μM.
- 11. The method according to embodiment 7, wherein the concentration of CHIR is at least about 3.1 μM.
- 12. A method according to embodiment 7, wherein the concentration of CHIR is at least about 3.2 μM.
- 13. A method according to embodiment 7, wherein the concentration of CHIR is at least about 3.3 μM.
- 14. A method according to embodiment 7, wherein the concentration of CHIR is at least about 3.4 μM.
- 15. A method according to embodiment 7, wherein the concentration of CHIR is at least about 3.5 μM.
- 16. The method according to embodiment 7, wherein the concentration of CHIR is in the range of about 2-7 μM.
- 17. The method according to embodiment 7, wherein the concentration of CHIR is in the range of about 3-7 μM.
- 18. The method according to embodiment 7, wherein the concentration of CHIR is in the range of about 3.1-7 μM.
- 19. The method according to embodiment 7, wherein the concentration of CHIR is in the range of about 3.2-7 μM.
- 20. The method according to embodiment 7, wherein the concentration of CHIR is in the range of about 3.3-7 μM.
- 21. The method according to embodiment 7, wherein the concentration of CHIR is in the range of about 3.4-7 μM.
- 22. The method according to embodiment 7, wherein the concentration of CHIR is in the range of about 3.5-7 μM.
- 23. A method according to embodiment 7, wherein the concentration of CHIR is 2.5 μM.
- 24. A method according to embodiment 7, wherein the concentration of CHIR is 3 μM.
- 25. A method according to embodiment 7, wherein the concentration of CHIR is 3.1 μM.
- 26. A method according to embodiment 7, wherein the concentration of CHIR is 3.2 μM.
- 27. A method according to embodiment 7, wherein the concentration of CHIR is 3.3 μM.
- 28. A method according to embodiment 7, wherein the concentration of CHIR is 3.4 μM.
- 29. A method according to embodiment 7, wherein the concentration of CHIR is 3.5 μM.
- 30. A method according to embodiment 7, wherein the concentration of CHIR is 3.6 μM.
- 31. A method according to embodiment 7, wherein the concentration of CHIR is 3.7 μM.
- 32. A method according to embodiment 7, wherein the concentration of CHIR is 3.8 μM.
- 33. A method according to embodiment 7, wherein the concentration of CHIR is 3.9 μM.
- 34. A method according to embodiment 7, wherein the concentration of CHIR is about 4 μM.
- 35. A method according to embodiment 7, wherein the concentration of CHIR is about 4.5 μM.
- 36. A method according to embodiment 7, wherein the concentration of CHIR is about 5 μM.
- 37. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is at least 12 hours.
- 38. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is at least 24 hours.
- 39. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is at least 48 hours.
- 40. A method according to embodiment 37, wherein said incubation with CHIR is between 24 and 48 hours.
- 41. A method according to embodiment 37, wherein said incubation with CHIR is 24 hours.
- 42. A method according to embodiment 37, wherein said incubation with CHIR is 48 hours.
- 43. The method according to any one of the preceding embodiments, wherein the concentration of activin A is at least about 100 ng/ml, such as in the range of about 1-5000 ng/ml, such as in the range of about 1-1000 ng/ml, such as in the range of about 10-500 ng/ml or such as in the range of about 1-200 ng/ml.
- 44. The method according to embodiment 43, wherein the concentration of activin A is in a range of about 1-200 ng/ml.
- 45. The method according to embodiment 43, wherein the concentration of activin A is in a range of about 20-200 ng/ml.
- 46. The method according to embodiment 43, wherein the concentration of activin A is in a range of about 30-200 ng/ml.
- 47. The method according to embodiment 43, wherein the concentration of activin A is at least 25 ng/ml.
- 48. The method according to embodiment 43, wherein the concentration of activin A is about 140 ng/ml.
- 49. The method according to embodiment 43, wherein the concentration of activin A is about 120 ng/ml.
- 50. The method according to embodiment 43, wherein the concentration of activin A is about 100 ng/ml.
- 51. The method according to embodiment 43, wherein the concentration of activin A is about 80 ng/ml.
- 52. The method according to embodiment 43, wherein the concentration of activin A is about 60 ng/ml.
- 53. The method according to embodiment 43, wherein the concentration of activin A is about 40 ng/ml.
- 54. A method according to any one of the preceding embodiments, wherein said incubation with activin A is in the range of 12 hours to 5 days, such as at least 12 hours, such as at least 24 hours or at least 48 hours, or such as 3-4 days.
- 55. A method according to embodiment 54, wherein said incubation with activin A is at least 12 hours.
- 56. A method according to embodiment 54, wherein said incubation with activin A is 24 hours.
- 57. A method according to embodiment 54, wherein said incubation with activin A is 48 hours.
- 58. A method according to embodiment 54, wherein said incubation with activin A is 72 hours.
- 59. A method according to embodiment 54, wherein said incubation with activin A is 48 to 72 hours.
- 60. A method according to embodiment 54, wherein said incubation with activin A is 3-4 days.
- 61. A method according to any one of the preceding embodiments, wherein endodermal cells are obtained from said definitive endoderm cells.
- 62. A method according to embodiment 61, wherein said endoderm cells are hepatic endoderm cells, pancreatic endoderm cells, intestinal endoderm cells and/or lung endoderm cells.
- 63. A method according to embodiment 62, wherein said endoderm cells are hepatic endoderm cells.
- 64. A method according to embodiment 62, wherein said endoderm cells are pancreatic endoderm cells.
- 65. Definitive endodermal cells obtainable by the methods of embodiments 1-64.
- 66. Endodermal cells obtainable by the methods of embodiments 1-64.
- 67. Hepatic endoderm cells, pancreatic endoderm cells, intestinal endoderm cells and/lung endoderm cells according to embodiment 66.
- 68. Endodermal cells according to embodiment 66, wherein said cells are hepatic endoderm cells.
- 69. Endodermal cells according to embodiment 66, wherein said cells are pancreatic endoderm cells.
- 70. The method according to embodiments 1-64, wherein beta-catenin is activated by CHIR-induced Gsk3b inhibition.
- 71. Use of CHIR in a concentration of CHIR in the culture medium is at least 2 μM CHIR, such as in the range of 3.1-15 μM, or such as 3.1-7 μM, or such as 3.5-15 uM, or such as
- 72. Use of CHIR in a concentration of at least 3.1 uM in the culture medium, to induce primitive streak cells from embryonic stem cells.
- 73. Use of CHIR in a concentration in the range of 3.1-7 uM to induce definitive endoderm cells from embryonic stem cells.
- 74. Use of CHIR in a concentration in the range of 3.5-7 uM to induce definitive endoderm cells from embryonic stem cells.
- 75. Use of CHIR in a concentration of 3.5 uM to induce definitive endoderm cells from embryonic stem cells.
- 76. Use of CHIR in a concentration of 4 uM to induce definitive endoderm cells from embryonic stem cells.
- 77. Use of CHIR in a concentration of 4.5 uM to induce definitive endoderm cells from embryonic stem cells.
- 78. Use of CHIR in a concentration of 5 uM to induce definitive endoderm cells from embryonic stem cells.
- 79. Use according to embodiments 71-78, wherein said primitive streak expresses one or more of the following markers: Brachyury or Mixl1.
- 80. Use according to embodiments 71-78, wherein said definitive endoderm expresses one or more of the following markers Sox17.
Further embodiments of the present invention: - 81. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
- a. first priming step of incubating stem cells in a medium comprising at least 2 μM CHIR, wherein activin A is not present during said priming step; and
- b. second subsequent step of incubating stem cells in a medium comprising at least 25 ng/ml activin A.
- 82. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
- a. first priming step of at least 12 hours, of incubating stem cells in a medium comprising at least 2 μM CHIR, wherein activin A is not present during said priming step; and
- c. second subsequent step of at least 12 hours, of incubating stem cells in a medium comprising at least 25 ng/ml activin A.
- 83. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
- b. first priming step of at least 24 hours, of incubating stem cells in a medium comprising at least 2 μM CHIR, wherein activin A is not present during said priming step; and
- d. second subsequent step of at least 24 hours, of incubating stem cells in a medium comprising at least 25 ng/ml activin A.
- 84. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
- a. first priming step of incubating stem cells in a medium comprising at least 3.1 μM CHIR, wherein activin A is not present during said priming step; and
- b. second subsequent step of incubating stem cells in a medium comprising at least
- 25 ng/ml activin A.
- 85. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
- a. first priming step of incubating stem cells in a medium comprising at least 3.5 μM CHIR, wherein activin A is not present during said priming step; and
- b. second subsequent step of incubating stem cells in a medium comprising at least 25 ng/ml activin A.
- 86. The methods according to any one of the preceding embodiments, wherein said stem cells are embryonic stem cells or induced pluripotent stem cells.
- 87. The method according to embodiment 86, wherein said stem cells are human embryonic stem cells.
- 88. The method according to embodiment 86, wherein said stem cells are induced pluripotent stem cells.
- 89. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is at least about 2, at least about 2.5 uM, at least about 3 uM, at least about 3.1 μM, such as in the range of about 3.1-15 μM, or such as about 3.5-7 μM or such as about 3.5-6 μM, or such as about 3.5-5 μM.
- 90. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is at least about 3.1 μM.
- 91. A method according to any one of the preceding embodiments, wherein the concentration of CHIR is at least about 3.2 μM.
- 92. A method according to any one of the preceding embodiments, wherein the concentration of CHIR is at least about 3.3 μM.
- 93. A method according to any one of the preceding embodiments, wherein the concentration of CHIR is at least about 3.4 μM.
- 94. A method according to any one of the preceding embodiments, wherein the concentration of CHIR is at least about 3.5 μM.
- 95. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is in the range of about 3.1-7 μM.
- 96. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is in the range of about 3.2-7 μM.
- 97. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is in the range of about 3.3-7 μM.
- 98. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is in the range of about 3.4-7 μM.
- 99. The method according to any one of the preceding embodiments, wherein the concentration of CHIR is in the range of about 3.5-7 μM.
- 100. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is at least 24 hours.
- 101. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is at least 48 hours.
- 102. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is between 24 and 48 hours.
- 103. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is 24 hours.
- 104. A method according to any one of the preceding embodiments, wherein said incubation with CHIR is 48 hours.
- 105. The method according to any one of the preceding embodiments, wherein the concentration of activin A is in a range of about 25-200 ng/ml.
- 106. The method according to any one of the preceding embodiments, wherein the concentration of activin A is in a range of about 30-200 ng/ml.
- 107. The method according to any one of the preceding embodiments, wherein the concentration of activin A is about 100 ng/ml.
- 108. The method according to any one of the preceding embodiments, wherein the concentration of activin A is about 80 ng/ml.
- 109. The method according to any one of the preceding embodiments, wherein the concentration of activin A is about 60 ng/ml.
- 110. The method according to any one of the preceding embodiments, wherein the concentration of activin A is about 40 ng/ml.
- 111. The method according to any one of embodiments, wherein the concentration of activin A is at least about 110 ng/ml.
- 112. A method according to any one of the preceding embodiments, wherein said incubation with activin A is in the range of 12 hours to 5 days, such as at least 12 hours, such as at least 24 hours or at least 48 hours, or such as 3-4 days.
- 113. A method according to any one of the preceding embodiments, wherein said incubation with activin A is at least about 24 hours.
- 114. A method according to any one of the preceding embodiments, wherein said incubation with activin A is about 24 hours.
- 115. A method according to any one of the preceding embodiments, wherein said incubation with activin A is about 48 hours.
- 116. A method according to any one of the preceding embodiments, wherein said incubation with activin A is about 72 hours.
- 117. A method according to any one of the preceding embodiments, wherein said incubation with activin A is about 48 to about 72 hours.
- 118. A method according to any one of the preceding embodiments, wherein said incubation with activin A is about 3-4 days.
- 119. A method according to any one of the preceding embodiments, wherein endodermal cells are obtained from said definitive endoderm cells.
- 120. A method according to embodiment 119, wherein said endoderm cells are hepatic endoderm cells, pancreatic endoderm cells, intestinal endoderm cells and/or lung endoderm cells.
- 121. A method according to embodiment 120, wherein said endoderm cells are hepatic endoderm cells.
- 122. A method according to embodiment 120, wherein said endoderm cells are pancreatic endoderm cells.
- 123. Definitive endodermal cells obtainable by the methods of embodiments 81-122.
- 124. Endodermal cells obtainable by the methods of embodiments 81-122.
- 125. Hepatic endoderm cells, pancreatic endoderm cells, intestinal endoderm cells and/lung endoderm cells according to embodiment 124.
- 126. Endodermal cells according to embodiment 124, wherein said cells are hepatic endoderm cells.
- 127. Endodermal cells according to embodiment 124, wherein said cells are pancreatic endoderm cells.
- 128. The method according to embodiments 81-122, wherein beta-catenin is activated by CHIR-induced Gsk3b inhibition.
- 129. Use of CHIR in a specific concentration to induce primitive streak cells from stem cells.
- 130. Use of CHIR in a specific concentration to induce definitive endoderm cells from stem cells.
- 131. Use according to embodiments 129-130, wherein the concentration of CHIR in the culture medium is at least 2 μM CHIR.
- 132. Use according to embodiments 129-131, wherein the concentration of CHIR in the culture medium is at least 2 μM CHIR, such as in the range of 2-7 μM, such as 3 μM or such as 4 μM.
- 133. Use of CHIR in a concentration in the range of 2-7 uM to induce definitive endoderm cells from embryonic stem cells.
- 134. Use of CHIR in a concentration in the range of 3-7 uM to induce definitive endoderm cells from embryonic stem cells.
- 135. Use of CHIR in a concentration in the range of 3.5-7 uM to induce definitive endoderm cells from embryonic stem cells.
- In one embodiment, the pancreatic endocrine cells obtainable by the method according to the invention are insulin producing cells, optionally together with cells differentiated towards glucagon, somatostatin, pancreatic polypeptide, and/or ghrelin producing cells. As used herein, “insulin producing cells” refers to cells that produce and store or secrete detectable amounts of insulin. “Insulin producing cells” can be individual cells or collections of cells.
- In another embodiment, the cell population comprising pancreatic cells is obtained from a somatic cell population. In some aspects the somatic cell population has been induced to de-differentiate in to an embryonic-like stem (ES, e.g., a pluripotent) cell. Such de-differentiated cells are also termed induced pluripotent stem cells (IPS).
- In another embodiment, the cell population comprising pancreatic cells is obtained from embryonic stem (ES, e.g., pluripotent) cells. In some aspects the cell population comprising pancreatic cells is pluripotent cells such as ES like-cells.
- In another embodiment, the cell population comprising pancreatic cells is embryonic differentiated stem (ES or pluripotent) cells. Differentiation takes place in embryoid bodies and/or in monolayer cell cultures or a combination thereof.
- In another embodiment, the cell population is a population of stem cells. In some aspects the cell population is a population of stem cells differentiated to the pancreatic endocrine lineage.
- Stem cells are undifferentiated cells defined by their ability at the single cell level to both self-renew and differentiate to produce progeny cells, including self-renewing progenitors, non-renewing progenitors, and terminally differentiated cells. Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation and to contribute substantially to most, if not all, tissues following injection into blastocysts.
- Stem cells are classified by their developmental potential as: (1) totipotent, meaning able to give rise to all embryonic and extraembryonic cell types; (2) pluripotent, meaning able to give rise to all embryonic cell types; (3) multi-potent, meaning able to give rise to a subset of cell lineages, but all within a particular tissue, organ, or physiological system (for example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self-renewal), blood cell restricted oligopotent progenitors and all cell types and elements (e.g., platelets) that are normal components of the blood); (4) oligopotent, meaning able to give rise to a more restricted subset of cell lineages than multi-potent stem cells; and (5) unipotent, meaning able to give rise to a single cell lineage (e.g., spermatogenic stem cells).
- A protocol for obtaining pancreatic cells from stem cells is exemplified by, but not limited to, the protocols described in D'Amour, K. A. et al. (2006), Nat Biotechnol 24, 1392-401; Jiang, J. et al. (2007), Stem Cells 25, 1940-53; and Kroon, E. et al. (2008), Nat Biotechnol 26, 443-452.
- A protocol for obtaining pancreatic cells from somatic cells or somatic cells induced to de-differentiate into pluripotent cells such as ES like-cells is exemplified by, but not limited to, the protocols described in Aoi, T. et al. (2008), Science 321 (no. 5889), 699-702; D'Amour, K. A. et al. (2006), Nat Biotechnol 24, 1392-401; Jiang, J. et al. (2007), Stem Cells 25, 1940-53; Kroon, E. et al. (2008), Nat Biotechnol 26, 443-452; Takahashi, K. et al. (2007), Cell 131, 861-72; Takahashi, K., and Yamanaka, S. (2006), Cell 126, 663-76; and Wernig, M. et al. (2007), Nature 448, 318-24.
- As used herein “differentiate” or “differentiation” refers to a process where cells progress from an undifferentiated state to a differentiated state, from an immature state to a less immature state or from an immature state to a mature state. For example, early undifferentiated embryonic pancreatic cells are able to proliferate and express characteristics markers, like Pdx1, Nkx6.1, and Ptf1a. Mature or differentiated pancreatic cells do not proliferate and do secrete high levels of pancreatic endocrine hormones or digestive enzymes. E.g., fully differentiated beta cells secrete insulin at high levels in response to glucose. Changes in cell interaction and maturation occur as cells lose markers of undifferentiated cells or gain markers of differentiated cells. Loss or gain of a single marker can indicate that a cell has “matured or fully differentiated.” The term “differentiation factor” refers to a compound added to pancreatic cells to enhance their differentiation to mature endocrine cells also containing insulin producing beta cells. Exemplary differentiation factors include hepatocyte growth factor, keratinocyte growth factor, exendin-4, basic fibroblast growth factor, insulin-like growth factor-1, nerve growth factor, epidermal growth factor platelet-derived growth factor, and glucagon-
like peptide 1. In some aspects differentiation of the cells comprises culturing the cells in a medium comprising one or more differentiation factors. - As used herein, “human pluripotent stem cells” (hPS) refers to cells that may be derived from any source and that are capable, under appropriate conditions, of producing human progeny of different cell types that are derivatives of all of the 3 germinal layers (endoderm, mesoderm, and ectoderm). hPS cells may have the ability to form a teratoma in 8-12 week old SCID mice and/or the ability to form identifiable cells of all three germ layers in tissue culture. Included in the definition of human pluripotent stem cells are embryonic cells of various types including human blastocyst derived stem (hBS) cells in 30 literature often denoted as human embryonic stem (hES) cells, (see, e.g., Thomson et al. (1998), Heins et. al. (2004), as well as induced pluripotent stem cells (see, e.g. Yu et al., (2007) Science 318:5858); Takahashi et al., (2007) Cell 131(5):861). The various methods and other embodiments described herein may require or utilise hPS cells from a variety of sources. For example, hPS cells suitable for use may be obtained from developing embryos. Additionally or alternatively, suitable hPS cells may be obtained from established cell lines and/or human induced pluripotent stem (hiPS) cells.
- As used herein “hiPS cells” refers to human induced pluripotent stem cells. As used herein, the term “blastocyst-derived stem cell” is denoted BS cell, and the human form is termed “hBS cells”. In literature the cells are often referred to as embryonic stem cells, and more specifically human embryonic stem cells (hESC). The pluripotent stem cells used in the present invention can thus be embryonic stem cells prepared from blastocysts, as described in e.g. WO 03/055992 and WO 2007/042225, or be commercially available hBS cells or cell lines. However, it is further envisaged that any human pluripotent stem cell can be used in the present invention, including differentiated adult cells which are reprogrammed to pluripotent cells by e.g. the treating adult cells with certain transcription factors, such as OCT4, SOX2, NANOG, and LIN28 as disclosed in Yu, et al., 2007, Takahashi et al. 2007 and Yu et al 2009.
- As used herein “feeder cells” are intended to mean supporting cell types used alone or in combination. The cell type may further be of human or other species origin. The tissue from which the feeder cells may be derived include embryonic, fetal, neonatal, juvenile or adult tissue, and it further includes tissue derived from skin, including foreskin, umbilical chord, muscle, lung, epithelium, placenta, fallopian tube, glandula, stroma or breast. The feeder cells may be derived from cell types pertaining to the group consisting of human fibroblasts, fibrocytes, myocytes, keratinocytes, endothelial cells and epithelial cells. Examples of specific cell types that may be used for deriving feeder cells include embryonic fibroblasts, extraembryonic endodermal cells, extraembryonic mesoderm cells, fetal fibroblasts and/or fibrocytes, fetal muscle cells, fetal skin cells, fetal lung cells, fetal endothelial cells, fetal epithelial cells, umbilical chord mesenchymal cells, placental fibroblasts and/or fibrocytes, placental endothelial cells,
- As used herein, the term “MEF cells” is intended to mean mouse embryonic fibroblasts.
- As used herein, “CHIR”, “Chir” or “Chir99021”, is a patented commercially available
glycogen synthase kinase 3 beta (Gsk3b) inhibitor covered in U.S. Pat. No. 6,417,185 and described by Goff, D. A., et al. (2002) Inhibitors ofglycogen synthase kinase 3. -
- 136. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
- a. incubating stem cells in a medium comprising at least 2 μM CHIR; and
- b. subsequently incubating stem cells in a medium comprising activin A.
- 137. A method according to embodiment 136, wherein activin A is not present during said incubation with CHIR.
- 138. A method according to embodiments 136-137, wherein said medium is RPMI-1640.
- 139. A method according to any of embodiments 136-138, wherein said stem cells are embryonic stem cells.
- 140. A method according to any of embodiments 136-139, wherein the concentration of CHIR is at least 2 μM, such as in the range of 2-7 μM, or such as 3 μM or such as 4 μM.
- 141. A method according to any of embodiments 136-140, wherein said incubation with
- CHIR is at least 12 hours, such as 24 hours.
- 142. A method according to any of embodiments 136-141, wherein said incubation with activin A is in the range of 12 hours to 5 days, such as at least 12 hours, such as at least 24 hours or at least 48 hours, or such as 3-4 days.
- 143. A method according to any of embodiments 136-142, wherein specific endodermal cells are obtained from said definitive endoderm cells.
- 144. A method according to embodiment 143, wherein said specific endoderm cells are pancreatic endoderm cells.
- 145. Definitive endodermal cells obtainable by the methods of embodiment 136-144.
- 146. Specific endodermal cells obtainable by the methods of embodiment 136-145.
- 147. Use of CHIR in a specific concentration to induce primitive streak cells from stem cells.
- 148. Use of CHIR in a specific concentration to induce definitive endoderm cells from stem cells.
- 149. Use according to embodiments 147-148, wherein the concentration of CHIR in the culture medium is at least 2 μM CHIR.
- 150. Use according to embodiments 147-148, wherein the concentration of CHIR in the culture medium is at least 2 μM CHIR, such as in the range of 2-7 μM, such as 3 μM or such as 4 μM.
- 151. Use of CHIR in a concentration in the range of 2-7 uM to induce definitive endoderm cells from embryonic stem cells.
- 152. Use of CHIR in a concentration in the range of 3-7 uM to induce definitive endoderm cells from embryonic stem cells.
- 153. Use of CHIR in a concentration in the range of 3.5-7 uM to induce definitive endoderm cells from embryonic stem cells.
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
- All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
- The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
- D'Am: D'Amour protocol (Kroon et al., 2008)
DE: definitive endoderm
bFGF: basic fibroblast growth factor (FGF2)
Gsk3b:glycogen synthase kinase 3 beta
hBSC; human blastocyst-derived stem cells
hESC: human embryonic stem cells
hIPSC: human induced pluripotent cells
hPSC: human pluripotent stem cells
KO-SR: knockout serum replacement
RNA: ribonucleic acid
PCR: polymerase chain reaction
PS: primitive streak
SOX17: SRY (sex determining region Y)-box 17 - The DE protocol was confirmed in two different feeder free (DEF, mTeSR) culture systems and one feeder dependent (MEF-ES) culture system.
- DEF hESC/iPS Culture System
- Human embryonic stem (hES) cells SA121 and chIPS4 (Cellartis) were grown on human fibronectin (Sigma) in DEF culture media (Cellartis) with 30 ng/ml bFGF (Invitrogen) and 10 ng/ml Noggin (Peprotech) in 6-96 well plates. Cells were single cell passaged with Rock inhibitor Y-27632 (Calbiochem) and seeded at a density of 40000 cells/cm2 for experiments. Experiments were initiated 4d after passage.
- mTeSR Culture System
- hES cells (SA121) were cluster passaged from feeders (MEFs) to Matrigel (BD Biosciences) in mTeSR1 media (Cell Signaling Techologies) and passaged further with Dispase (BD Biosciences) according to the culture system protocol. DE was initiated once clusters started to touch eachother
- hES cells (SA121) were passaged on gelatine-coated plates pre-seeded with MEFs in hES media (KO-DMEM, PEST, Glutamax, NEAA, 2-mercaptoethanol, KO serum replacement, 10 ng/ml bFGF). DE was initiated at 80% confluency.
- Confluent cultures were washed once in RPM11640 (Invitrogen) before 24 hour pretreatment with 0.5-7 μM CHIR99021 (Stemgent) in RPMI. Control cells were left untreated in RPMI and D'Amour cells were either left in RPMI or treated with AA (Peprotech)+Wnt3a (R&D Systems) without pre-treatment depending on experimental setup.
- After 24 hours, pretreated and control cells were washed once with RPMI before adding 100 ng/ml AA in RPMI. D'Amour cells were also treated with 100 ng/ml AA but with 0.2% FBS instead of B27. 24 h later, 2% B27 (Invitrogen) was added to the AA media for 2-3d. Control cells were treated with B27 to prevent cell death and D'Amour cells with 2% FBS according to published protocol. Media was changed every day.
- When cells were further differentiated to PE, the DE protocol was applied in T75 cell culture flasks and reseeded after 4d of DE culture at a density of 200K in DE media. 1d later, cells were washed once before addition of PE media (RPMI1640+12% KOSR+64 ng/ml bFGF) according to published protocol (Ameri et al 2010).
- Overview of the CHIR Definitive Endoderm protocol can be found in
FIG. 1 . The protocol has been confirmed in 7 different cell lines: SA121, SA181, SA461, SA167 (hESC) and chIPS2, chIPS3, chIPS4 (hiPSC). -
TABLE 1 CHIR DE cell culture protocol Ctrl CHIR protocol D'Amour Day1 medium RPM11640 CHIR99021, Activin A (AA) 0.1 % PEST 3 uM 100 ng/ml RPMI1640 Wnt3a 0.1% PEST 25 ng/ml RPMI1640 0.1 % PEST Day 2 medium Activin A (AA) Activin A (AA) Activin A (AA) 100 ng/ ml 100 ng/ ml 100 ng/ml RPMI1640 RPMI1640 RPMI1640 0.1% PEST 0.1% PEST 0.2% FBS 0.1 % PEST Day 3 medium Activin A (AA) Activin A (AA) Activin A (AA) 100 ng/ ml 100 ng/ ml 100 ng/ml RPMI1640 RPMI1640 RPMI1640 2 % B27 2% B27 0.2% FBS 0.1% PEST 0.1% PEST 0.1% PEST Day 1: Cells were washed carefully in prewarmed (37° C.) RPMI before starting the differentiation. Day 1 medium was premixed (CHIR 3 μM in prewarmed RPMI + PEST) and gently added to cell culture. Volumes were adjusted according to plate formats.Day 2: Cells were washed carefully in prewarmed (37° C.) RPMI before media change. Day 2 medium was premixed (100 ng/ml Activin A in prewarmed RPMI + 0.1% PEST) and gently added to cell culture.Day 3: Day 3&4 mediums were premixed (100 ng/ml Activin A and 2% B27 in prewarmed RPMI + 0.1% PEST) and gently added to cell culture. Day 4: DE was harvested or reseeded for further differentiation. Cells were checked under the microscope every day. - RNA samples were collected after 24 h pre-treatment (D1), after 1 day of AA treatment (D2) and after 1-2d of AA+B27 treatment (D3-4). Total RNA was extracted with the Rneasy Plus Mini kit (Qiagen) and quantitative real-time PCR was performed using the StepOnePLus system (Applied Biosystems).
- Cells were washed in PBS+/+ and fixed in 4% formaldehyde for 30 min (10% formaline, VWR). The cells were then washed again three times in PBS and left in PBS (4° C.) until staining. Fixed cells were washed with PBS once, then permeabilized with 0.5% Triton X-100 in PBS for 6 min, washed in PBS and blocked with TNB buffer (0.1M Tris-HCL pH 7.5, 0.15M NaCl, 0.5% Blocking Reagent (Perkin Elmer)) for 30 min. Primary antibodies (goat-anti-SOX17 (AF1924, RnD Systems); goat-anti-Brachyury (AF2085, RnD Systems); mouse-anti-OCT4 (sc5279, SantaCruz Biotechnology); goat-anti-PDX1 (AB47383, Abcam)) were added in 0.1% TritonX-100+PBS for 1 h in RT or 4° C. O/N. After a thorough washing step in PBS, secondary antibodies were added together with DAPI in 0.1% Triton X-100+PBS for 45 min at RT, washed thoroughly in PBS and left in PBS until photodocumentation.
- Undifferentiated SA121 hES and chIPS4 iPS cells in DEF media (D0) were cultured either in RPMI without CHIR (Ctrl D1) or treated for 24 h with CHIR in RPMI (CHIR D1). The cells were then washed to ensure absence of CHIR and then both conditions were treated with 1d AA (Ctrl and CHIR d2). After 1d CHIR treatment, PS markers such as Brachyury (T), MIXL1, EOMES and GSC were highly upregulated compared to non pre-treated cells (
FIG. 2A-C ). T fold inductions after 24 h CHIR treatment spanned between 500-100000 compared to undifferentiated cells (d0). T protein levels were also confirmed with ICC (FIG. 2C ). - 1d after AA addition (D2), markers that together are indicative of DE formation such as SOX17, CXCR4, FOXA2 and CER were also highly upregulated compared to non-pretreated cells despite addition of AA to both conditions (
FIGS. 3A ,B), Sox17-f old inductions after CHIR pretreatment spanned between 10000-3500000 compared to undifferentiated cells (D0, n>60). The efficiency levels for both T and SOX17 were highly robust (n>60) and confirmed with IHC and SOX17 quantifications (FIG. 2C and Table 2.). The CHIR pre-treatment step resulted in a remarkably rapid induction of SOX17 after AA treatment. SOX17 expression peaked already after one day of AA treatment when cells were subjected to CHIR for 24 h before AA induction. Cells in AA-containing media that were not pre-treated with CHIR (ctrl) did not show same speed or efficiency in Sox17 induction. - CHIR has a direct capacity to induce PS markers after 24 h treatment (D1) and resulted in a remarkably higher ability for AA to induce DE when added (D2). Brachyury was greatly repressed once AA was added indicating that the cells were differentiating in a highly stepwise order.
-
TABLE 2 OCT4 and SOX17 protein ICC quantifications in undifferentiated hES SA121/chlPS4 cells OCT4 SOX17 SA121 chlPS4 SA121 chlPS4 ICC % D'Amour CHIR D'Amour CHIR D'Amour CHIR D'Amour CHIR Undiff 97.5 98.3 0 0 D1 91.9 97.7 94.3 91.2 0 0 8.3 0.9 D2 55.2 2.4 14 3.1 61.6 72.1 75.2 68.8 D3 44.1 0.2 26.2 3.7 80.4 93.1 77.6 91.5
Table 2 shows D1-3 of DE induction according to D'Amour (protocol as described in Kroon et al 2008) and cells treated with 3 uM CHIR (CHIR D1) prior to addition of ActivinA (CHIR D2-3). - hES SA121 and ChIPS4 cells were treated with either CHIR (3 μM), BIO (0.5 uM), Wnt3a (200 ng/ml) or AA alone (100 ng/ml) for 24 h prior to AA addition to show CHIR specificity (d1). Additionally, D'Amour (protocol as described in Kroon et al 2008) was tested in parallel.
- CHIR treatment significantly upregulated Brachyury expression after 24 h (
FIGS. 4A ,C). After AA addition (D2), Brachyury was reduced and SOX17 was upregulated (FIG. 4B ). hES cells treated with AA or BIO did not survive untilday 3. - The data clearly illustrated that PS transition (upregulation of Brachyury) and DE induction (upregulation of SOX17) were both accelerated and much higher after CHIR treatment compared to pretreatment with growth factors such as AA and Wnt3a. Pretreatment of the cells with another small molecule Gsk3b inhibitor (BIO) did not elicit the same effect and the cells did not survive until d3. Treatment with either Wnt3a and BIO instead of CHIR delayed the Brachyury (PS) response (upregulated D2) compared to CHI R treatment (data not shown). Furthermore, these substances induced both Brachyury and SOX17 gene expression with significantly lower efficiency and cells treated with AA or BIO did not survive until d3. This protocol was also highly superior to the previously published D'Amour protocol.
- CHIR Vs. D'Amour Protocol (DE and PE Induction)
- Undifferentiated ChIPS4 cells (d0) were either pre-treated for 24 h with CHIR (3 uM) or directly exposed to AA (100 ng/ml) and Wnta3a (25 ng/ml) according to Kroon et al 2008. The cells were then washed and AA was added for 1-4d. See Table 1 for detailed setup.
- CHIR treatment was superior in upregulating both T (mRNA D1) and SOX17 after CHIR pre-treatment (mRNA, ICC D3) compared to D'Amour (
FIG. 5 and Table 2). In addition, the most striking difference between the protocols could be seen in terms of morphology with a much higher degree of cell death during D'Amour treatment. To further strengthen the results, a quantification of SOX17 protein expression was thus performed. chIPS4 cells treated with either the CHIR- or D'Amour-protocol were fixed and stained using a SOX17-specific ab and the images were quantified in respect of total amounts and the percentage of SOX17-positive cells. As shown inFIG. 6D , 91.5% of the CHIR-treated cells were found to be positive for SOX17 whereas only 77.6% of the D'Amour-treated cells showed SOX17 positive staining d3. In addition, the total amount of CHIR pre-treated cells was 25% higher than the number seen after D'Amour treatment. - The decrease of OCT4 expression was also analyzed in chIPS4 cells using both qPCR and qICC. The data clearly shows that the CHIR-protocol is more sufficient in reducing OCT4 expression at both mRNA and protein levels (
FIG. 5E , F). - To further compare the efficiency between the CHIR- and D'Amour protocols, chIPS4 cells differentiated to DE, using either of the two protocols, were further differentiated towards pancreatic endoderm (PE) by using a previously published PE differentiation protocol (Ameri et al 2010). Seven days after the induction of PE differentiation the cells were fixed and analyzed by ICC using a PDX1 specific antibody. The results showed very modest PDX1-staining in the D'Amour-treated cells whereas the staining was evident in the CHIR pre-treated cells (data not shown). In parallel, mRNA was collected from the cells and the PDX1 expression was analyzed by real-time PCR. Concordantly with the ICC results, almost no PDX1 mRNA expression was found in D'Amour-treated cells while a clear expression was seen in the CHIR-differentiated cells (
FIG. 5G ). The experiment was repeated twice in both cell lines (FIGS. 5G ,H). - Cells were pre-treated 1d with either RPMI (ctrl),
CHIR 3 uM,CHIR 3 uM+AA 100 ng/ml or 100 ng/ml AA+25 ng/ml Wnt3a (D'Amour) prior to addition of AA+/−Wnt3a (25 ng/ml) d2 and AA d3 (Table 3). B27 was added in Ctrl and CHIR d3 and FBS to D'Amour d2-3. -
TABLE 3 Protocols used for DE induction Condition D 1 D 2 D 3Ctrl RPMI AA AA + B27 D'Amour AA + Wnt3a AA + FBS AA + FBS DE prot CHIR AA AA + B27 DE prot + Wnt d 2CHIR AA + Wnt3a AA + B27 CHIR + AA CHIR + AA AA AA + B27 - The data shows that absence of Wnt3a after CHIR treatment does not affect SOX17 induction negatively (
FIG. 6A , C). However, AA exclusion after CHIR treatment maintained Brachyury expression (data not shown) and limited further progression toward DE. - Adding AA on top of CHIR during pre-treatment did not show additive effects, the protocol stability was however negatively affected with high inter-experimental variation in terms of DE induction. A negative effect on cell survival D1 was also often seen when combining CHIR and AA during pretreatment (see cell morphology D1,
FIG. 6D ), Adding CHIR on top of D'Amour D1 also showed reduced SOX17 expression D2 compared to cells pre-treated with CHIR (FIG. 6B ). - CHIR pretreatment replaces the requirement of both Wnt3a and AA during the first day of differentiation toward DE and also has a stabilizing effect leading to a more robust protocol.
- CHIR and exogenous AA may have counteracting effects that reduce overall efficiency and/or target different cell populations differently, resulting in higher levels of heterogeneity within the cell culture and increased inter-experimental variability. This suggests that PS induction/transition before adding AA to the media is an important and novel step to enhance protocol efficiency and robustness.
- Chir was titrated at concentrations between 1-7 uM and analyzed after 24 h Chir treatment (D1) and after 2d of following AA treatment (D3). CHIR 0.5-1 uM and CHIR 7 uM did not survive d3.
-
- 1. After 24 h treatment, Brachyury induction was significantly seen in
CHIR 3 uM but not 1 uM (FIG. 7A ,C). - 2. 2d after AA treatment, downregulation of Brachyury expression was delayed in
CHIR 1 uM (FIG. 7A ) whereas Sox17 expression was significantly lower (7B,D)
- 1. After 24 h treatment, Brachyury induction was significantly seen in
- The data indicates that PS formation is delayed at Chir concentrations under 1 uM, unabling further progression toward DE when AA is added.
- DE Induction after CHIR Pre-Treatment in Other Cell Culture Systems
- The effect on OCT4 downregulation and T/SOX17 upregulation D3 after CHIR pretreatment was also superior to the D'Amour protocol in other hESC feeder free culture systems such as mTeSR (
FIG. 8A Table 4) and in hESCs grown on MEF feeders (FIG. 9 ). -
TABLE 4 Oct4 and Sox17 expression in the mTeSR system Immunostainings and OCT4/SOX17+ cell quantification Control D'Amour Chir 7μM Exp Oct4 Sox17 Oct4 Sox17 Oct4 Sox17 ME16b 35.51 24.6 9.86 64.77 6.97 62.62 ME18b 79.86 0.43 14.31 57.46 2.53 82.87 ME21a 64.63 13.9 31.13 56.82 0.95 91.36 Mean 60 13.0 18.4 59.7 3.5 79.0 -
- Ameri, J., A. Stahlberg, et al. (2010). “FGF2 specifies hESC-derived definitive endoderm into foregut/midgut cell lineages in a concentration dependent manner.” Stem Cells 28(1): 45-56.
- Chung et al. (2008). “Human embryonic stem cells lines generated without embryo destruction”.
Cell Stem Cell 2. - Geens et al. (2009). “Human embryonic stem cell lines derived from single blastomeres of two 4-cell stage embryos”. Human reproduction.
- Hanna, J., A. W. Cheng, et al. (2010). “Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs.” Proc Natl Acad Sci USA 107(20): 9222-9227.
- Jiang, J., M. Au, et al. (2007). “Generation of insulin-producing islet-like clusters from human embryonic stem cells.” Stem Cells 25(8): 1940-1953.
- Klimanskaya et al. (2006). “Human embryonic stem cell lines derived from single blastomeres”. Nature Letters.
- Kroon, E., L. A. Martinson, et al. (2008). “Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin secreting cells in vivo.” Nat Biotechnol 26(4): 443-452.
- Mazumdar, J., W. T. O'Brien, et al. (2010). “02 regulates stem cells through Wnt/beta-catenin signalling.” Nat Cell Biol 12(10): 1007-1013.
- Sato, N., L. Meijer, et al. (2004). “Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signalling by a pharmacological GSK-3-specific inhibitor.” Nat Med 10(1): 55-63.
- Wagner, R. T., X. Xu, et al. (2010). “Canonical Wnt/beta-Catenin Regulation of Liver Receptor Homolog-1 (Lrh-1) Mediates Pluripotency Gene Expression.” Stem Cells.
- Yang, J., A. L. van Oosten, et al. (2010). “Stat3 Activation is limiting for reprogramming to ground state pluripotency.” Cell Stem Cell 7(3): 319-328.
Claims (17)
1. A method for differentiation of stem cells into definitive endoderm comprising the steps of:
incubating stem cells in a medium comprising at least 2 μM CHIR, wherein activin A is not present; and
subsequently incubating stem cells in a medium comprising activin A.
2. The method according to claim 1 , wherein said medium is RPMI-1640.
3. The method according to claim 1 , wherein said stem cells are embryonic stem cells or induced pluripotent stem cells.
4. The method according to claim 1 , wherein the concentration of CHIR is at least about 2.5 μM.
5. The method according to claim 1 , wherein the concentration of CHIR is at least about 3.1 μM.
6. The method according to claim 1 , wherein the concentration of CHIR is in a range selected from the group consisting of about 2.5-15 μM, about 3.1-15 μM, about 3.1-7 μM, 3.5-7 μM, about 3.5-6 μM, and about 3.5-5 μM.
7. The method according to claim 1 , wherein the concentration of CHIR is at least about 3.5 μM.
8. The method according to claim 1 , wherein said incubation with CHIR is at least 24 hours.
9. The method according to claim 1 , wherein said incubation with activin A is at least 24 hours.
10. The method according to claim 1 , wherein said incubation with activin A is 48 to 72 hours.
11. The method according to claim 1 , wherein endodermal cells are obtained from said definitive endoderm cells.
12. The method according to claim 11 , wherein said endoderm cells are pancreatic endoderm cells.
13. Pancreatic endoderm cells obtainable by the method of claim 12 .
14. The method according to claim 1 , wherein the concentration of CHIR in the culture medium is at least 3 μM.
15. The method according to claim 1 , wherein the concentration of CHIR in the culture medium is in a range selected from the group consisting of about 2-15 μM, about 3-15 μM, about 3.1-15 μM, about 3.1-7 μM, about 3.5-15 μM, and about 3.5-7 μM.
16. A method for inducing primitive streak cells from embryonic stem cells by using CHIR in a concentration of at least 2 μM in the culture medium.
17. A method for inducing definitive endoderm cells from embryonic stem cells by using CHIR in a concentration in the range of 3.5-7 μM.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/694,040 US20200190477A1 (en) | 2011-06-21 | 2019-11-25 | Efficient induction of definitive endoderm from pluripotent stem cells |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11170713.9 | 2011-06-21 | ||
EP11170713 | 2011-06-21 | ||
US201161501351P | 2011-06-27 | 2011-06-27 | |
PCT/EP2012/062013 WO2012175633A1 (en) | 2011-06-21 | 2012-06-21 | Efficient induction of definitive endoderm from pluripotent stem cells |
US201414127296A | 2014-04-07 | 2014-04-07 | |
US15/705,705 US10487313B2 (en) | 2011-06-21 | 2017-09-15 | Efficient induction of definitive endoderm from pluripotent stem cells |
US16/694,040 US20200190477A1 (en) | 2011-06-21 | 2019-11-25 | Efficient induction of definitive endoderm from pluripotent stem cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/705,705 Continuation US10487313B2 (en) | 2011-06-21 | 2017-09-15 | Efficient induction of definitive endoderm from pluripotent stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200190477A1 true US20200190477A1 (en) | 2020-06-18 |
Family
ID=47422055
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/127,296 Abandoned US20140234963A1 (en) | 2011-06-21 | 2012-06-21 | Efficient induction of definitive endoderm from pluripotent stem cells |
US15/705,705 Active US10487313B2 (en) | 2011-06-21 | 2017-09-15 | Efficient induction of definitive endoderm from pluripotent stem cells |
US16/694,040 Abandoned US20200190477A1 (en) | 2011-06-21 | 2019-11-25 | Efficient induction of definitive endoderm from pluripotent stem cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/127,296 Abandoned US20140234963A1 (en) | 2011-06-21 | 2012-06-21 | Efficient induction of definitive endoderm from pluripotent stem cells |
US15/705,705 Active US10487313B2 (en) | 2011-06-21 | 2017-09-15 | Efficient induction of definitive endoderm from pluripotent stem cells |
Country Status (6)
Country | Link |
---|---|
US (3) | US20140234963A1 (en) |
EP (1) | EP2723852B1 (en) |
JP (1) | JP6312591B2 (en) |
CN (2) | CN103890167A (en) |
ES (1) | ES2902650T3 (en) |
WO (1) | WO2012175633A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012175633A1 (en) | 2011-06-21 | 2012-12-27 | Novo Nordisk A/S | Efficient induction of definitive endoderm from pluripotent stem cells |
CN104903440B (en) | 2012-09-03 | 2018-04-06 | 诺和诺德股份有限公司 | Using small molecule pancreas entoderm is produced from multipotential stem cell |
GB201317869D0 (en) * | 2013-10-09 | 2013-11-20 | Cambridge Entpr Ltd | In vitro production of foregut stem cells |
MA45747A (en) | 2016-02-24 | 2019-01-02 | Novo Nordisk As | GENERATION OF FUNCTIONAL BETA CELLS FROM ENDOCRINE PROGENITORS DERIVED FROM HUMAN PLURIPOTENT SOUH CELLS |
EP3679124A1 (en) * | 2017-09-07 | 2020-07-15 | Stemonix Inc. | Efficient differentiation of human stem cells to definitive endoderm |
RU2020111055A (en) | 2017-09-11 | 2021-09-17 | Ново Нордиск А/С | ENRICHMENT WITH CELLS JOINT EXPRESSING NKX6.1 AND C-PEPTIDE OBTAINED IN VITRO FROM STEM CELLS |
US20210230554A1 (en) | 2018-08-30 | 2021-07-29 | Novo Nordisk A/S | Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors |
CN113728090B (en) | 2019-04-08 | 2024-04-05 | 诺和诺德股份有限公司 | Pancreatic endoderm generation from stem cell-derived definitive endoderm |
EP4061929A1 (en) | 2019-11-22 | 2022-09-28 | Novo Nordisk A/S | Spin-aggregated neural microspheres and the application thereof |
CN116018150A (en) | 2020-08-28 | 2023-04-25 | 诺和诺德股份有限公司 | Methods for screening in vitro populations of stem cell derived beta-like cells and novel markers therefor |
WO2024008810A1 (en) | 2022-07-06 | 2024-01-11 | Novo Nordisk A/S | Differentiation of stem cells to pancreatic endocrine cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009012428A2 (en) * | 2007-07-18 | 2009-01-22 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
ATE274510T1 (en) | 1998-06-19 | 2004-09-15 | Chiron Corp | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS |
CA2447015A1 (en) | 2001-05-15 | 2002-11-21 | Rappaport Family Institute For Research In The Medical Sciences | Insulin producing cells derived from human embryonic stem cells |
CN101240262A (en) | 2001-12-07 | 2008-08-13 | 杰龙公司 | Islet cells from human embryonic stem cells |
US20050095703A1 (en) | 2001-12-28 | 2005-05-05 | Henrik Semb | Method for the establishment of a pluripotent human blastocyst - derived stem cell line |
MX2009009225A (en) * | 2003-12-23 | 2009-09-28 | Cythera Inc | Definitive endoderm. |
US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
EP1740612B1 (en) | 2004-04-27 | 2019-08-07 | Viacyte, Inc. | Pdx1 expressing endoderm |
EP1945758A2 (en) | 2005-10-07 | 2008-07-23 | Cellartis AB | A method for obtaining a xeno-free hbs cell line |
SG10201405380QA (en) | 2006-03-02 | 2014-10-30 | Cythera Inc | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
EP2021462B1 (en) | 2006-04-28 | 2019-01-09 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
US8741643B2 (en) * | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
US20090298169A1 (en) | 2006-06-02 | 2009-12-03 | The University Of Georgia Research Foundation | Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems |
CA2676044C (en) * | 2007-01-30 | 2019-10-22 | University Of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc) |
JP5646990B2 (en) | 2007-04-23 | 2014-12-24 | ストワーズ インスティテュート フォー メディカル リサーチ | Methods and compositions for stem cell self-renewal |
US9080145B2 (en) * | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
AU2008280143B2 (en) | 2007-07-20 | 2014-04-17 | Cellartis Ab | A novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts stem cells |
CN101952415B (en) | 2007-07-31 | 2017-06-27 | 生命扫描有限公司 | The differentiation of human embryo stem cell |
JP6087043B2 (en) | 2007-07-31 | 2017-03-01 | ライフスキャン・インコーポレイテッドLifescan,Inc. | Differentiation of pluripotent stem cells using human feeder cells |
US9005962B2 (en) * | 2007-08-24 | 2015-04-14 | The University Court Of The University Of Edinburgh | Regionalised endoderm cells and uses thereof |
US7939322B2 (en) | 2008-04-24 | 2011-05-10 | Centocor Ortho Biotech Inc. | Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm |
US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
WO2009137844A2 (en) | 2008-05-09 | 2009-11-12 | Vistagen Therapeutics, Inc. | Pancreatic endocrine progenitor cells derived from pluripotent stem cells |
EP2297319B1 (en) * | 2008-06-03 | 2015-10-07 | Viacyte, Inc. | Growth factors for production of definitive endoderm |
US20090298178A1 (en) * | 2008-06-03 | 2009-12-03 | D Amour Kevin Allen | Growth factors for production of definitive endoderm |
EP2942392B1 (en) | 2008-06-30 | 2018-10-03 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
MX2011000123A (en) | 2008-06-30 | 2011-02-25 | Centocor Ortho Biotech Inc | Differentiation of pluripotent stem cells. |
US20100028307A1 (en) | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
US8278105B2 (en) * | 2008-09-09 | 2012-10-02 | University Of Southern California | Induction, propagation and isolation of liver progenitor cells |
CN101684454B (en) * | 2008-09-25 | 2012-08-15 | 中国科学院上海生命科学研究院 | Method for preparing and separating definitive endoderm |
AU2009308967C1 (en) | 2008-10-31 | 2017-04-20 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
ES2727950T3 (en) | 2008-10-31 | 2019-10-21 | Janssen Biotech Inc | Differentiation of human embryonic stem cells in pancreatic endocrine lineage |
CN102282254B (en) | 2008-11-14 | 2015-12-16 | 维赛特公司 | Come from the encapsulating of the pancreatic cell of human pluripotent stem cells |
WO2010091241A2 (en) | 2009-02-06 | 2010-08-12 | President And Fellows Of Harvard College | Compositions and methods for promoting the generation of definitive endoderm |
EP3904505A1 (en) | 2009-04-22 | 2021-11-03 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
KR20120047866A (en) | 2009-05-27 | 2012-05-14 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Generation of genetically corrected disease-free induced pluripotent stem cells |
CN102482640B (en) | 2009-07-20 | 2015-03-11 | 詹森生物科技公司 | Differentiation Of Human Embryonic Stem Cells |
KR20170118969A (en) | 2009-07-20 | 2017-10-25 | 얀센 바이오테크 인코포레이티드 | Differentiation of human embryonic stem cells |
MX343786B (en) | 2009-12-23 | 2016-11-22 | Janssen Biotech Inc | Differentiation of human embryonic stem cells. |
KR101923537B1 (en) | 2009-12-23 | 2018-11-29 | 얀센 바이오테크 인코포레이티드 | Differentiation of human embryonic stem cells |
WO2011081222A1 (en) | 2009-12-29 | 2011-07-07 | 武田薬品工業株式会社 | Method for manufacturing pancreatic-hormone-producing cells |
CN107189979B (en) | 2010-03-01 | 2021-05-04 | 詹森生物科技公司 | Method for purifying cells derived from pluripotent stem cells |
WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
SG10201503652WA (en) | 2010-05-12 | 2015-08-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
WO2011160066A1 (en) | 2010-06-17 | 2011-12-22 | Regents Of The University Of Minnesota | Production of insulin producing cells |
SG10201506264QA (en) | 2010-08-12 | 2015-09-29 | Janssen Biotech Inc | Treatment of diabetes with pancreatic endocrine precursor cells |
PL2853589T3 (en) | 2010-08-31 | 2018-05-30 | Janssen Biotech, Inc | Differentiation of human embryonic stem cells |
AU2011296381B2 (en) | 2010-08-31 | 2016-03-31 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
US9062292B2 (en) | 2010-09-13 | 2015-06-23 | Enzo Life Sciences Inc. | Mutant T7 polymerases |
WO2012070014A2 (en) | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
WO2012078153A1 (en) | 2010-12-08 | 2012-06-14 | Viacyte, Inc. | Agents and methods for inhibiting human pluripotent stem cell growth |
CA2816495C (en) | 2010-12-15 | 2020-10-13 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
WO2012175633A1 (en) | 2011-06-21 | 2012-12-27 | Novo Nordisk A/S | Efficient induction of definitive endoderm from pluripotent stem cells |
-
2012
- 2012-06-21 WO PCT/EP2012/062013 patent/WO2012175633A1/en active Application Filing
- 2012-06-21 US US14/127,296 patent/US20140234963A1/en not_active Abandoned
- 2012-06-21 EP EP12735227.6A patent/EP2723852B1/en active Active
- 2012-06-21 ES ES12735227T patent/ES2902650T3/en active Active
- 2012-06-21 JP JP2014516354A patent/JP6312591B2/en active Active
- 2012-06-21 CN CN201280040881.9A patent/CN103890167A/en active Pending
- 2012-06-21 CN CN201810066827.0A patent/CN108220224A/en active Pending
-
2017
- 2017-09-15 US US15/705,705 patent/US10487313B2/en active Active
-
2019
- 2019-11-25 US US16/694,040 patent/US20200190477A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009012428A2 (en) * | 2007-07-18 | 2009-01-22 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
Also Published As
Publication number | Publication date |
---|---|
WO2012175633A1 (en) | 2012-12-27 |
CN108220224A (en) | 2018-06-29 |
EP2723852A1 (en) | 2014-04-30 |
JP2014519832A (en) | 2014-08-21 |
EP2723852B1 (en) | 2021-11-17 |
CN103890167A (en) | 2014-06-25 |
US10487313B2 (en) | 2019-11-26 |
JP6312591B2 (en) | 2018-04-18 |
US20140234963A1 (en) | 2014-08-21 |
ES2902650T3 (en) | 2022-03-29 |
US20180002668A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10487313B2 (en) | Efficient induction of definitive endoderm from pluripotent stem cells | |
CA2694956C (en) | Pluripotent stem cell differentiation by using human feeder cells | |
USRE43876E1 (en) | Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm | |
RU2650813C2 (en) | Use of epinephrine ligands to differentiate pancreatic endoderm cells | |
CA2809305C (en) | Differentiation of pluripotent stem cells | |
RU2668814C2 (en) | Methods of producing cells of definitive and pancreatic endoderm | |
US20100028307A1 (en) | Pluripotent stem cell differentiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |